Clinical Pharmacology & Therapeutics

Article	Citations
Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia	454
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	269
Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID‐19: A Nationwide Cohort Study in South Korea	214
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients	183
Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease	169
Collaborative Real‐World Evidence Among Regulators: Lessons and Perspectives	117
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	106
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	105
Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers	100
Optimal Trough Concentration of Tacrolimus in Pediatric Patients With Primary Nephrotic Syndrome	96
	84
Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration	82
Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women	81
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information	80
A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real‐World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluat	77
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers	68
Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy	62
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported	60
The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity	58
Artificial Neural Network vs. Pharmacometric Model for Population Prediction of Plasma Concentration in Real‐World Data: A Case Study on Valproic Acid	56
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice	56
Patient‐Centric Clinical Pharmacology: A Journey from Discovery to Recovery	55
	52
The European List of Key Medicines for Medical Education: A Modified Delphi Study	51
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study	51

Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance	50
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV	49
Trends in Clinical Pharmacology and Therapeutics	46
Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men	46
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	45
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies	45
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants	44
Neurodegenerative Diseases: The Value of Early Predictive End Points	44
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review	43
Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project	42
Advancing Innovations in Biosimilars	42
Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021	41
Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level	40
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	39
On the Manufacturers of Biosimilars in Asia	39
Evaluating Prognostic Value of Dynamics of Circulating Lactate Dehydrogenase in Colorectal Cancer Using Modeling and Machine Learning	38
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations	38
Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4	37
A Modern Curriculum for Training Scientists in Model‐Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists	37
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts	37
Highlights	36
Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study	36
Issue Information	34
ASCPT NEWS	34
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model	33
A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants	33
Non‐Labeled, Stable Labeled, or Radiolabelled Approaches for Provision of Intravenous Pharmacokinetics in Humans: A Discussion Piece	33
	32
Polygenic Risk Scores for Blood Pressure to Assess the Risk of Severe Bevacizumab‐Induced Hypertension in Cancer Patients (Alliance)	32
Current Perspectives on Data Sharing and Open Science in Pharmacogenomics	32
Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge Gap	32
Oncology Combination Dose‐Finding Study Design for Targeted and Immuno‐Oncology Therapies	32
Issue Information	31
In this Issue	31
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	31
	31
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization	31
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors	30
Identification of Risk Factors for COVID‐19 Hospitalization in Patients With Anti‐Rheumatic Drugs: Results From a Multicenter Nested Case Control Study	30
No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost	29
	29
Development of an External Control Arm Using Electronic Health Record‐Based Real‐World Data to Evaluate the Efficacy of COVID‐19 Treatment	29
Regulator‐Requested Non‐Interventional Postauthorization Safety and Effectiveness Studies for Oncology Drugs: A Systematic Review	28
Highlights	28
Issue Information	28
Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology	28
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	27
Congenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancy: A Systematic Review	27
Nafamostat Reduces the Incidence of post‐ERCP Pancreatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials	27
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	27

Highlights	27
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	26
	26
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	26
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned	26
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	26
The Value of Clinical Pharmacogenomic Guidelines That Recommend Standard of Care Over Genotype‐Based Prescribing	26
Methodology for Good Machine Learning with Multi‐Omics Data	26
Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients	26
Pharmacogenomic Prescribing Guidelines: Are They Always Useful?	26
Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer	26
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	25
	25
Local Ancestry‐Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations	25
Keyword Index	24
Optimization of Vaccine Responses in Solid Organ Transplant Recipients	24
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population	24
Issue Information	24
In this Issue	24
In this Issue	24
Diversity in Clinical Pharmacology Coming of Age	24
Response to: Real‐World Data on the Risk of Ventricular Arrhythmias with Sulfonamides	24
ASCPT News	23
ASCPT News	23
ASCPT News	23
Highlights	23
Highlights	22
In This Issue	22
ASCPT News	22
ASCPT News	21
ASCPT News	21
In This Issue	21
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example	21
Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress‐Testing Renal Function Range in Real World Patients	20
Issue Information	20
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	20
Impact of Drug Recalls on Patients in The Netherlands: A 5‐Year Retrospective Data Analysis	20
In This Issue	20
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination	20
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	20
Understanding the Mechanism and Extent of Transplacental Transfer of (−)‐∆9‐Tetrahydrocannabinol (THC) in the Perfused Human Placenta to Predict In Vivo Fetal THC Exposure	20
Issue Information	20
OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005	20
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	20
Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers	20
The Changing Landscape for Human Absorption, Metabolism, and Excretion: Practical Experiences From a Data Analysis of 500 Studies	19
Off‐Label, but on‐Evidence? A Review of the Level of Evidence for Pediatric Pharmacotherapy	19
Issue Information	19
Patterns of Prescription Medication Use during the First Trimester of Pregnancy in the United States, 1997–2018	19
Highlights	18
	18
Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021	18
Exposure‐Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product	18
Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary	18
Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions	18
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities	18
IQ Survey Results on Current Industry Practices: Part 2—Quantitative Evaluations of Immunogenicity Assessment	18
Trends in FDA Transporter‐Based Post‐Marketing Requirements and Commitments Over the Last Decade	18
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary	18
Population Pharmacokinetic Modeling for Ceftazidime‐Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older	17
How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study	17
DrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing	17
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination	17
The Use of Real‐World Evidence for Regulatory Decisions in China	17
Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma	17
	17
Response to Rowland et al. and Achour et al.	17
Issue Information	17
Identifying Potential Therapeutic Applications and Diagnostic Harms of Increased Bilirubin Concentrations: A Clinical and Genetic Approach	17
Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins	16
Mapping the miRNA‐mRNA Interactome in Human Hepatocytes and Identification of Functional mirSNPs in Pharmacogenes	16
Nutrimetric Validation of Solanidine as Dietary‐Derived CYP2D6 Activity Marker In Vivo	16
Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions	16
Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase	16
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	16
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics	16
ICH S7B In Vitro Assays Do Not Address Mechanisms of QTC Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QTC Studies	16
First‐in‐Human Dose Selection for T‐Cell Engaging Bispecific Antibodies	16
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	16
EXOGENOUS Sex Hormones and Sex Hormone Receptor Modulators in COVID‐19: Rationale and Clinical Pharmacology Considerations	16

Clinical Pharmacology of Cannabinoid Therapeutics: Drug Interactions and Side Effects	16
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	16
A Biological Basis for Pharmacokinetics: The Remote Sensing and Signaling Theory	15
Expanding Approved Patient Populations for Rare Disease Treatment Using In Vitro Data	15
Clinical Pharmacology Worldwide: A Global Health Perspective	15
Trends in Postpartum Opioid Prescribing: A Time Series Analysis	15
Uncontrolled Extensions of Clinical Trials and the Use of External Controls—Scoping Opportunities and Methods	15
Machine Learning: A New Approach for Dose Individualization	15
Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection	15
Lorlatinib Exposed: A Far From Optimal Dose	15
Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease	15
Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real‐World Population	15
Leveraging Real‐World Data for EMA Qualification of a Model‐Based Biomarker Tool to Optimize Type‐1 Diabetes Prevention Studies	15
Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19	15
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes	15
Effect of Lipid‐Lowering Drugs on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Dyslipidemia: A Retrospective Cohort Study	15
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?	15
Disruptive Innovations to Achieve Health Equity Through Healthcare and Research Transformation	15
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling	14
Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare Diseases	14
Progress in Pharmacometrics Implementation and Regulatory Integration in Africa: A Systematic Review	14
The Promise of Health for All: A Collaborative Model to Close Treatment Gaps for Neglected Diseases	14
Medications and Acute Hemolysis in G6PD‐Deficient Patients – A Real‐World Study	14
First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor	14
Ongoing Pharmacological Developments in SLC6A1 Research & Treatment	14
Racial and Ethnic Disparities in Antihypertensive Medication Prescribing Patterns and Effectiveness	14
	14
Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov	14
Mycophenolic Acid Exposure Determines Antibody Formation Following SARS‐CoV‐2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study	14
HIGHLIGHTED ARTICLES	14
Translational Population‐Pharmacodynamic Modeling of a Novel Long‐Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia	13
Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities	13
pyDarwin: A Machine Learning Enhanced Automated Nonlinear Mixed‐Effect Model Selection Toolbox	13
Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real‐World Pharmacovigilance and Randomized Clinical Trials	13
Correction to Exploring the Use of Serum‐Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting P	13
Correction to “Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting”	13
The Origin of First‐in‐Class Drugs: Innovation Versus Clinical Benefit	13
Corrigendum: The Drug Titration Paradox is Simpson’s Paradox	13
Concomitant Use of Sodium‐Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection	13
Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies	13
Evaluation of Switch‐to‐Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real‐World Retrospective Cohort Study	13
Real‐World Evidence to Support EU Regulatory Decision Making—Results From a Pilot of Regulatory Use Cases	13
High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention	13
American Society for Clinical Pharmacology and Therapeutics	13
Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease	13
Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease	13
Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer	13
Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer	13
PharmVar GeneFocus: CYP3A5	13
Pharmacokinetic Modeling and Model‐Based Hypothesis Generation for Dose Optimization of Clonidine in Neonates With Neonatal Opioid Withdrawal Syndrome	13
Real‐World Progression‐Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real‐World Data	13
Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives	12
Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial	12
The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway	12
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers	12
Dose Adjustment in Patients with Liver Cirrhosis – Comparison of Two Different Modeling Approaches	12
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies	12
Impact of Multiple Prescriptions With Anticholinergic Properties on Adverse Clinical Outcomes in the Elderly: A Longitudinal Cohort Study in Taiwan	12
Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs	12
TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real‐World Clinical Results	12
From Plan to Pivot: How Model‐Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials	12
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy	12
Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost	12
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans	12
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update	12
Beyond the Individual: Community‐Centric Approaches to Increase Diversity in Biomedical Research	11
Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease	11
Artificial Intelligence: From Buzzword to Useful Tool in Clinical Pharmacology	11
Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer	11
Genome‐wide Association Studies Categorized by Class of Antihypertensive Drugs Reveal Complex Pathogenesis of Hypertension with Drug Resistance	11
PharmVar GeneFocus: CYP2A6	11
Frequency and Nature of Generic “Design Around” of Brand‐Name Patents in the United States	11
Pharmacogenomic Clinical Decision Support: A Review, How‐to Guide, and Future Vision	11
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects	11
Changes in S‐Citalopram Plasma Concentrations Across Pregnancy and Postpartum	11
Considerations for Human ADME Strategy and Design Paradigm Shift(s) – An Industry White Paper	11
Development and Bioequivalence of 3D‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine	11
Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities	11
Roadmap to 2030 for Drug Evaluation in Older Adults	11
Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome‐Wide Interaction Meta‐Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies	11
Rational Clinical Dose Selection of Adeno‐Associated Virus‐Mediated Gene Therapy Based on Allometric Principles	11
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	11
Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs	11
Whole Body PBPK Modeling of Remdesivir and Its Metabolites to Aid in Estimating Active Metabolite Exposure in the Lung and Liver in Patients With Organ Dysfunction	11
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective	11
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator	11
Issue Information	11
Chat GPT vs. Clinical Decision Support Systems in the Analysis of Drug–Drug Interactions	10
Preserving Timely Generic Drug Competition with Legislation on “Skinny Labeling”	10
Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021	10
New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium	10
Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT‐2 Inhibitors: A Nationwide Population Cohort Study	10
Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes	10
Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study	10
Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability	10